If your doctor recently prescribed Repatha to help lower your "bad" LDL cholesterol and reduce the risk of heart disease, you may be wondering how it fits into the bigger picture of heart health.

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current ...

March 13 (Reuters) - Amgen Inc said on Monday its injection Repatha significantly reduced the need for patients to undergo a procedure to reduce bad cholesterol, according to the findings of a ...

If approved by the European Commission (EC), Repatha would be the first PCSK9 inhibitor in Europe with the option of a single monthly injection. Repatha was the first PCSK9 inhibitor to gain marketing ...

The FINANCIAL — Amgen on July 11 announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge), a new, ...

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...

Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha ® (evolocumab) Injection, the first proprotein ...

Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...

Amgen’s PCSK9 inhibitor Repatha has fresh phase 3 outcomes data and a broader reimbursement footprint, keeping the injectable cholesterol drug relevant against cheap statins and rival antibodies. For ...

Repatha is the second in a new class of drugs called PCSK9 inhibitors to win FDA approval The drug is a second line of treatment for those who can't take or don't respond to widely used statins for ...

AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...